A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Efficacy And Safety of MPDL3280A (Anti-PD-L1 Antibody) In Combination With Carboplatin+Paclitaxel or MPDL3280A In Combination with Carboplatin+ NAB-Pacilitaxel Versus Carboplatin+Paclitaxel in Chemotherapy-Naïve Patients with Stage IV Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
Freehold, Sparta

Sponsor
Genentech

Protocol Number
GO29437

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910